SEC Comment Letter 0000000000-23-002765 to NeuBase Therapeutics, Inc. (CIK 0001173281)
NeuBase Therapeutics, Inc. (CIK 0001173281)
Date: March 20, 2023 · CIK: 0001173281 · Accession: 0000000000-23-002765
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo March 20, 2023 Todd Branning Chief Financial Officer NeuBase Therapeutics, Inc. 350 Technology Drive Pittsburgh, PA 15219 Re:NeuBase Therapeutics, Inc. Form 10-K for the Year Ended September 30, 2022 Filed December 21, 2022 File No. 1-35963 Dear Todd Branning: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
March 20, 2023
Todd Branning
Chief Financial Officer
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
Re:NeuBase Therapeutics, Inc.
Form 10-K for the Year Ended September 30, 2022
Filed December 21, 2022
File No. 1-35963
Dear Todd Branning:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences